TickerFacts.

Recursion Pharmaceuticals, Inc. (RXRX): EBITDA

Operating income plus depreciation and amortization for the same annual period and currency, computed by TickerFacts from the filed figures. Not the company's adjusted EBITDA; a year without both inputs is left out.

-$564.43M
Year ended 2025-12-31
-$465.65M
Trailing 12 months to 2026-06-30
2019-12-31: -$59.95M2020-12-31: -$80.67M2021-12-31: -$174.37M2022-12-31: -$233.97M2023-12-31: -$325.66M2024-12-31: -$442.51M2025-12-31: -$564.43M-$564.43M
2019-12-31 EBITDA (USD) 2025-12-31
Period endedEBITDAChange YoYSource filing
2025-12-31-$564.43Mn/m2026-02-25, From 2025-01-01
2024-12-31-$442.51Mn/m2026-02-25, From 2024-01-01
2023-12-31-$325.66Mn/m2026-02-25, From 2023-01-01
2022-12-31-$233.97Mn/m2025-02-28, From 2022-01-01
2021-12-31-$174.37Mn/m2024-02-29, From 2021-01-01
2020-12-31-$80.67Mn/m2023-02-27, From 2020-01-01
2019-12-31-$59.95Mn/a2022-03-23, From 2019-01-01

EBITDA at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedEBITDAChange YoY
Recursion Pharmaceuticals, Inc. (RXRX)2025-12-31-$564.43Mn/m
Autolus Therapeutics plc (AUTL)2025-12-31-$262.25Mn/m
Vir Biotechnology, Inc. (VIR)2025-12-31-$467.65Mn/m
MeiraGTx Holdings plc (MGTX)2025-12-31-$93.43Mn/m
4D Molecular Therapeutics, Inc. (FDMT)2025-12-31-$154.85Mn/m
Champions Oncology, Inc. (CSBR)2026-04-30$237.0K-96.2%
Sutro Biopharma, Inc. (STRO)2025-12-31-$151.04Mn/m
ImmunityBio, Inc. (IBRX)2025-12-31-$240.50Mn/m
Agenus Inc (AGEN)2025-12-31-$10.17Mn/m

Compare RXRX, AUTL, VIR, MGTX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗